General
Preferred name
AZACITIDINE
Synonyms
5-Azacytidine ()
Vidaza ()
AZA ()
Azacitidine(Vidaza) ()
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one ()
Azacitidine (5-Azacytidine) ()
5-AzaC,Ladakamycin, AZA,5-Aza, CC-486,NSC 102816,5-Azacytidine ()
Azacitidine mylan ()
U-18,496 ()
NSC-102816 ()
Ladakamycin ()
Onureg ()
Azacitidine accord ()
Azacitidine betapharm ()
Azacitidina ()
5-azacitidine ()
U-18496 ()
Azacitidine kabi ()
Azacitidine celgene ()
P&D ID
PD001379
CAS
320-67-2
1401238-97-8
Tags
available
drug
prodrug
Approved by
PMDA
EMA
FDA
First approval
2004
Drug indication
Myelodysplastic syndrome
Acute myeloid leukemia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION DNA methyltransferase and RNA inhibitor. Azacitidine inhibits DNA methylation in vitro , but not by directly interacting with the methyltransferase enzyme DNMT1. (GtoPdb)
MOA Azacitidine (5-azacytidine) is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine may induce antineoplastic activity by inhibition of DNA methyltransferase at low doses and cytotoxicity through incorporation into RNA and DNA at high doses. Covalent binding to DNA methyltransferase results in hypomethylation of DNA and prevents DNA synthesis. As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein, resulting in cell death.
ROE Following IV administration of radioactive azacitidine to 5 cancer patients, the cumulative urinary excretion was 85% of the radioactive dose.; Fecal excretion accounted for <1% of administered radioactivity over three days. Mean excretion of radioactivity in urine following SC administration of 14C-azacitidine was 50%.
PRICE 29
DESCRIPTION 5-Azacytidine (Ladakamycin) is a cytidine nucleoside analog, a DNA methylation inhibitor with specificity. 5-Azacytidine regulates gene expression by decreasing the level of DNA methylation. 5-Azacytidine induces autophagy and has antitumor activity.
DESCRIPTION inhibitor of DNA methyltransferase (Informer Set)
DESCRIPTION Azacitidine is a pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. It is used to treat certain subtypes of myelodysplastic syndrome. (Enamine Bioactive Compounds)
DESCRIPTION ROCK inhibitor ; improves the efficiency of fibroblast reprogramming and induction of iPSCs (Tocris Bioactive Compound Library)
DESCRIPTION DNA methyltransferase inhibitor (Tocriscreen Plus)
DESCRIPTION DNA methyltransferase inhibitor (LOPAC library)
Cell lines
11
Organisms
1
Compound Sets
29
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
Informer Set
JUMP-Target 1 Compound Set
LINCS compound set
LOPAC library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
External IDs
648
Properties
(calculated by RDKit )
Molecular Weight
244.08
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
4
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-3.17
TPSA
143.72
Fraction CSP3
0.62
Chiral centers
4.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
DNMT1
RNA
DNA
DNA (cytosine-5)-methyltransferase 3A
DNA (cytosine-5)-methyltransferase 1
DNMT1, DNMT3A
DNMT3A
Autophagy,DNA Methyltransferase,Nucleoside Analog/Antimetabolite
Compound status
FDA
Target Type
Enzymes
Selectivity
DNA methyltransferase
MOA
DNA Methyltransferase inhibitor
Inhibitor
Antimetabolites
Apoptosis Inducers
DNA Methyltransferase (DNMT) Inhibitors
"DNMT1
DNA Methyltransferase (DNMT) Inhibitors"
Primary Target
DNA Methyltransferases
Member status
member
Indication
myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)
Disease Area
hematologic malignancy, hematology
Therapeutic Class
Anticancer Agents
Source data